As your weight loss progresses and abdominal fat decreases, you may need to transition to other sites or adjust your technique to maintain proper subcutaneous delivery
The STEP-4 trial of semaglutide showed roughly two-thirds of lost weight returning within a year of discontinuation
Baggio LL, Drucker DJ (2007a) Biology of Incretins: GLP-1 and GIP
What I found in the existing data is that the metabolic improvements from retatrutide, including reduced visceral fat, lower triglycerides, and improved insulin sensitivity, all point toward a cardiovascular benefit profile rather than a risk profile
NovoCare self-pay is the FDA-approved brand-name middle path, cheaper than retail but still two to three times compounded
Endocrinology 151 , 143152 (2010)